Molecular Diagnostics News and Research

RSS

ITL Group to celebrate 40 years of med-tech innovation at AACC

ITL Group’s global operation will be front and centre at the 69th Annual Scientific Meeting and Clinical Lab, from 29 July to 3 August in San Diego, California, marking its first appearance in 15 years.

From Vitl Life Science Solutions 1 Aug 2017

Siemens Healthineers- Siemens unveils new brand name for healthcare business

Today Siemens Healthcare unveiled its new brand name Siemens Healthineers. The new brand underlines Siemens Healthcare’s pioneering spirit and its engineering expertise in the healthcare industry.

From Siemens Healthineers Point of Care Diagnostics 26 Jul 2017

DiaSorin and Tecan partner to develop new platform for molecular diagnostics applications

DiaSorin and Tecan Group have announced that they have agreed to collaborate in a development under which DiaSorin will make use of Tecan’s Fluent Laboratory Automation Solution as its nucleic acid extraction platform.

From Tecan 5 Jul 2017

New 10-minute test uses drops of blood or saliva for early detection of cancers

Researchers at Ram Group's Israeli bio-sensor division have developed a new molecular diagnostics test for early detection of cancers that takes just ten minutes and uses just a couple drops of blood or saliva.

24 Jun 2017

Alinity: the future of diagnostics?

Diagnostic tests are critical as up to 60 to 70% of critical clinical decisions are influenced by diagnostic test results. It's of huge importance to the running of any healthcare system. Here at Abbott, we believe that providing clinicians with quick access to diagnostics information and insights can help them make quick clinical decisions around the appropriate treatment for a patient,

From Abbott Diagnostics 14 Jun 2017

New OpenArray system offers simultaneous detection of pathogens in blood samples

The emergence of new pathogens like West Nile Virus, Ebola, Dengue, and Zika, threaten human health on a global scale.

From Thermo Fisher Scientific - Microbiology 13 Jun 2017

Roche to showcase new solutions for lab innovation at EuroMedLab

Roche announced today that it will be showcasing new solutions for lab innovation and leadership at the 22nd IFCC–EFLM European Congress of Clinical Chemistry and Laboratory Medicines in Athens, Greece, 11–15 June.

From Roche Sequencing and Life Science 13 Jun 2017

Prolaris becomes first genetic test to receive Medicare coverage for favorable intermediate and low-risk prostate cancer

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that Palmetto GBA, a Medicare Administrative Contractor that assesses molecular diagnostic technologies, has issued a positive final Local Coverage Determination to expand Medicare coverage of the Prolaris test.

29 May 2017

Study identifies potent molecular mechanism for insecticide resistance in sandfly species

A study led by LSTM identifies a potent molecular mechanism for insecticide resistance in the world's most medically-important sandfly species and develops DNA-diagnostics for monitoring future impact on visceral leishmaniasis control and elimination programs.

5 May 2017

Myriad and Clovis ink deal on FDA-approved BRACAnalysis CDx test to identify patients with germline BRCA mutations for rucaparib treatment

Myriad Genetics, Inc. and Clovis Oncology, Inc. have announced a companion diagnostic collaboration to support a post-marketing regulatory commitment related to Clovis’ PARP inhibitor, Rubraca. Financial terms of the deal were not disclosed.

3 May 2017

Invivoscribe receives FDA approval for the LeukoStrat CDx FLT3 mutation assay companion diagnostic test for the selection of patients for Rydapt

Invivoscribe® Technologies Inc., a global company with more than 20 years of experience providing clonality and biomarker test solutions for the fields of oncology, personalized molecular diagnostics® and personalized molecular medicine®, today announces the premarket approval of LeukoStrat® CDx FLT3 Mutation Assay.

3 May 2017

Study finds high degree of discordance between Myriad Genetics and public database in BRCA1 and BRCA2 variant classifications

Myriad Genetics, Inc., a leader in molecular diagnostics and personalized medicine, today announced that new data comparing BRCA1 and BRCA2 variant classifications between Myriad Genetics and a commonly used public genetic database was published in the journal The Oncologist.

21 Apr 2017

New blood test can accurately, quickly identify genetic mutations linked to NSCLC

Identification of a specific genetic mutation in patients with non-small-cell lung cancer (NSCLC) helps clinicians select the best treatment option. Potential NSCLC patients usually undergo invasive tissue biopsy, which may often be unnecessary and delays treatment.

19 Apr 2017

Researchers develop blood test to detect intracranial bleeding in infants with abusive head trauma

Researchers at Children's Hospital of Pittsburgh of UPMC and University of Pittsburgh School of Medicine have developed and refined a blood test that could help clinicians identify infants who may have had bleeding of the brain as a result of abusive head trauma, sometimes referred to as shaken baby syndrome.

10 Apr 2017

Epigem partners with Northumbria University to develop disposable TB testing kit

Leading micro-engineering company Epigem today announced a new Knowledge Transfer Partnership with Northumbria University to develop a cost-effective tuberculosis (TB) testing kit.

From Epigem Ltd. 6 Apr 2017

ANGLE's Parsortix system shows high sensitivity, purity in gene expression analysis of head and neck cancers

ANGLE plc, the specialist medtech company, is delighted to announce that the University of Athens and Attikon University Hospital, Greece are today presenting highly encouraging results from their work with ANGLE’s Parsortix system in head and neck squamous cell carcinomas at the American Association for Cancer Research conference 2017, in Washington DC.

4 Apr 2017

QIAGEN announces commercialization of AdnaTest kit for clinical research in prostate cancer

QIAGEN N.V. today announced it is commercializing the Research use only AdnaTest Prostate Cancer Panel AR-V7 to detect the androgen receptor splice variant 7 (AR-V7) from liquid biopsies to investigate resistance to potential drugs for advanced prostate cancer.

From QIAGEN Manchester Limited 31 Mar 2017

Liquid biopsies that enable screening, early detection of cancer attract attention of investors

Interest is high in the development of blood-based tests that can be used to screen individuals for cancer. That isn't new, liquid biopsy industry has attracted attention and investment for the past few years.

28 Mar 2017

AMP releases new guidelines for validation of NGS-based oncology panels

The Association for Molecular Pathology, the premier global, non-profit molecular diagnostics professional society, today published consensus recommendations to help clinical laboratory professionals achieve high-quality sequencing results and deliver better care for cancer patients.

22 Mar 2017

Asynt’s non-ducted filtration and fume cabinets to aid development of portable diagnostic devices

Leading multinational life sciences tools and diagnostics developer - QuantuMDx has invested in the Asynt professional range of non-ducted laboratory filtration and fume cabinets which sit directly on benchtop surfaces

20 Mar 2017